ARHGEF38 as a novel biomarker to predict aggressive prostate cancer

Kun Liu; Aixiang Wang; Longke Ran; Wanfeng Zhang; Song Jing; Yujing Wang; Xianqin Zhang; Geli Liu; Wang Sen; Fangzhou Song

doi:10.1016/j.gendis.2019.03.004

您当前的位置：

首页 >

文章列表页 >

ARHGEF38 as a novel biomarker to predict aggressive prostate cancer

更新时间：2022-06-24

- ARHGEF38 as a novel biomarker to predict aggressive prostate cancer
- Genes & Diseases Vol. 7, Issue 2, (2020)
- 作者机构：
  
  1. Molecular Medicine and Cancer Research Center, Chongqing Medical University,Chongqing,China,400016
  2. Tianjin Key Institute of Urology, Department of Urology, Second Hospital of Tianjin Medical University,Tianjin,China,300162
  3. Department of Bioinformatics, Chongqing Medical University,Chongqing,China,400016
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2019.03.004
  CLC：
- Published：2020，
  
  Published Online：1 June 2020，
扫描看全文
Kun Liu, Aixiang Wang, Longke Ran, et al. ARHGEF38 as a novel biomarker to predict aggressive prostate cancer. [J]. Genes & Diseases 7(2).(2020)
DOI：

Kun Liu, Aixiang Wang, Longke Ran, et al. ARHGEF38 as a novel biomarker to predict aggressive prostate cancer. [J]. Genes & Diseases 7(2).(2020) DOI： 10.1016/j.gendis.2019.03.004.

摘要

Abstract

Prostate cancer (PCa) metastasis is considered the leading cause of cancer death in males. Therapeutic strategies and diagnosis for stage-specific PCa have not been well understood. Rho guanine nucleotide exchange factor 38 (ARHGEF38) is related to tumor cell polarization and is frequently expressed in PCa. Microarray data of PCa were downloaded from GEO and TCGA databases. A total of 243 DEGs were screened

of which

32 genes were upregulated. The results of enrichment analysis showed the participation of these DEGs in the tumor cell metastasis pathway. ARHGEF38 was significantly up-regulated in the four most prevalent cancers worldwide (

0.05)

and its expression was higher in the tumor samples with higher Gleason score (GS). IHC

qRT-PCR

and western-blot analyses showed the higher expression of ARHGEF38 in PCa than benign prostatic hyperplasia (BPH). In addition

IHC results demonstrated a higher expression of ARHGEF38 in high-grade PCa than the low-grade PCa.

关键词

Keywords

Gleason scoreImmunohistochemistryKaplan–Meier survivalPCa

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰